MedTrace Logo

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-12-23

No results posted yet for this study

Summary

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Conditions

  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression

Interventions

DRUG

Ruxolitinib

Given PO

Sponsors & Collaborators

Principal Investigators

  • William E Shomali, MD · Stanford Cancer Institute Palo Alto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2028-12-30
Completion
2028-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801434 on ClinicalTrials.gov